Table 2 Estimated gestational age and time to recurrence of Plasmodium falciparum (Pf) for novel and recrudescent infections for each anti-malarial treatment and including the distribution of intercalated Plasmodium vivax infections

Anti-malarial (action, years)^a

% >28 days

% >42 days

% >63 days

% (N)^c

Quinine monotherapy (short, 1994–2006)

17 [3–36]

47 [7–216]

21 [7–126]

25.4 (77/303)

10.6 (32/303)

5.0 (15/303)

33.0 (58)

Quinine + clindamycin (short, 1998–2009)

10 [4–24]

84 [28–201]

50 [21–122]

57.1 (4/7)

57.1 (4/7)

42.9 (3/7)

7.4 (13)

Artesunate monotherapy (short, 1995–2008)

21 [4–37]

54 [8–182]

22 [11–99]

30.6 (15/49)

12.2 (6/49)

4.1 (2/49)

21.6 (38)

Artesunate + Clindamycin (short, 1998–2009)

23^e [1–39]

49 [21–158]

28 [12–70]

45.5 (10/22)

27.3 (6/22)

9.1 (2/22)

26.1 (46)

Artemether + lumefantrine (medium, 2004–2006)

23 [13–36]

36 [15–140]

23 [14–63]

31.6 (6/19)

26.3 (5/19)

0.0 (0/19)

6.3 (11)

Artesunate + Atovaquone + proguanil (medium, 1999–2005)

23 [18–32]

67 [44–101]

49 [35–120]

100.0 (3/3)

66.7 (2/3)

33.3 (1/3)

1.7 (3)

Mefloquine monotherapy (long, 1994–1997)

26 [12–38]

25 [9–44]

22 [7–123]

27.8 (5/18)

5.6 (1/18)

5.6 (1/18)

0 (0)

DHA^f + Piperaquine (long, 2006–2008)

20 [8–34]

63 [35–180]

33 [21–49]

66.7 (4/6)

16.7 (1/6)

0.0 (0/6)

4.0 (7)

Artesunate + Mefloquine (long, 1995–2008)

28 [−0.4-39]

35 [20–43]

21 [−]

0.0 (0/1)

0.0 (0/1)

0.0 (0/1)

0 (0)